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COSTS OF LIVER TRANSPLANTATION: 
PRIMUM NON OBFUSCARE 
Van Thiel DH, Tarter R, Gavaler JS, Potanko W M  and 
Schude RR. Liver transplantation in adults. An analysis 
of costs and benefits at the University of Pittsburgh. 
Gastroenterology 1986; 90:211-216. 
EDITOR’S ABSTRACT 
The costs and benefits of liver transplantation 
in adult patients at the University of Pittsburgh 
were reviewed for the period from 1981 through 
1984. Indirect costs such as those to support the 
surgical and hepatology programs, the operating 
rooms and the clinical pathology department were 
ignored, and only those costs generated by the 
liver transplant program were considered in this 
analysis. Benefits to the patients are survival it- 
self. Over 8.5% of those who leave the hospital 
return to full-time employment or other useful 
activity, including normal, albeit complicated, 
pregnancies. Most deaths occur during the first 3 
months, after which there is a slow decline during 
the first year. Costs to the patient and/or the third 
party payers are enormous, and include evaluation 
as a transplant candidate, procurement of the do- 
nor liver, the transplantation itself and lifelong 
medical-surgical follow-up and immunosuppres- 
sion plus the management of the undesirable con- 
sequences of the whole procedure. Laboratory 
tests alone average over $52,000 per patient. The 
consumption of blood and blood products is great 
and averages 30 units per patient. Duration of 
hospital admissions averaged about 55 days per 
patient, of which about 10 were in intensive care 
units. Total dollar costs were not calculated, how- 
ever. The benefits to medicine are considerable in 
the acquisition of new knowledge and skills appli- 
cable to other disorders and other patients. The 
authors conclude that with further experience, the 
costs will decrease and the benefits will increase. 
COMMENTS 
The recent paper by Van Thiel et al. first promises to 
be quite interesting and important. In the introduction, 
they note: “The following is a cost-benefit analysis of 
liver transplantation as applied to a single institu- 
tion. . . .” Unfortunately, it is not a cost-benefit analysis, 
nor does it add significantly to our understanding of the 
costs associated with liver transplantation. 
The key element of cost-benefit analysis is that both 
the inputs and outputs are expressed in monetary terms 
(1). The application of cost-benefit analysis to medical 
problems requires the assignment of a dollar figure to a 
human life; this can be done, but only with obvious 
criticism (2). An alternate approach is cost-effectiveness 
analysis in which a cost is assigned to the health care 
process; but rather than assigning a dollar figure to a 
life, the life itself is used as the unit of measurement. 
Thus, cost-effectiveness analysis presents information 
such as the cost of colon cancer screening to detect one 
cancer of the colon, or to avert one cancer-related death. 
Additionally, both cost-benefit analysis and cost-effec- 
tiveness analysis use the patient as the unit of analysis. 
It is important to define both of these methods of analysis 
for several reasons: (i) they are the standard techniques 
employed by health services researchers; (ii) the defini- 
tion of cost-benefit analysis is quite exact; (iii) precise 
definitions permit assessment of the nature and signifi- 
cance of analysis of the costs of medical care. 
Despite their introduction, Van Thiel et al. performed 
neither a cost-benefit nor a cost-effectiveness analysis. 
They first describe the “costs” and “benefits” to a trans- 
plantation center. They note that because dollar values 
are “difficult to compare between institutions, the costs, 
whenever possible, will be reported in terms of number 
of personnel, days, or some other unit of service.” The 
costs to the institution are listed as the additional insti- 
tutional costs for such personnel as a senior surgeon, 
anesthesiologists, secretaries (etc.). The “benefits” to the 
institution (and participating physicians) include na- 
tional and international recognition, local publicity, the 
ability to attract faculty and the like. The authors then 
switch their orientation to the patient and attempt to 
identify costs and benefits. Patient-related “costs” in- 
clude such items as time spent in the ICU, units of blood, 
the costs of laboratory tests, preoperative hospital costs 
and posthospital hospital costs, where “costs” are ex- 
pressed in terms of charges. Aside from the obvious 
inconsistency in assigning personnel “costs” to the hos- 
pital and laboratory “costs” to the patient, the authors 
confuse the identification of costs in general. 
Despite the profession’s proclamation that liver trans- 
plantation is no longer an experimental technology, so- 
ciety appears to be incompletely convinced (3-5; Evans, 
R. W., Lancet 1983; 2:1306, Correspondence). The key 
question asked by society is: “DO the benefits justify the 
costs?” We live at a time of increasing concern about the 
costs of medical care. Liver transplantation is both high 
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cost and life saving for a small number of patients. It 
serves, therefore, as a bellwether condition. While phy- 
sicians have made great advances in the care of such 
patients, fewer advances have been made in our ability 
to arrive at the true costs of that care. Without knowing 
the true costs of care, society is concerned that the few 
patients who do benefit from liver transplantation siphon 
off a disproportionate amount of resources from other 
patients also in need of health care (6). 
Hospital “costs” can be expressed by a number of 
terms: accounting costs, economic costs and charges (7). 
The usual measure chosen when “costs” are discussed is 
to utilize hospital charges as a “cost” measure as illus- 
trated by Van Thiel et al. Charges are the prices set by 
a hospital for a small subset of private-paying patients 
and commercial third party payors. The charges have 
little, if anything to do with a hospital’s “costs.” The 
charge is a price set by the hospital in response to the 
market, it is usually well above “costs,” but in some 
patients it may actually be below “costs.” 
The distinction between economic costs and account- 
ing costs is critical when one evaluates technologies like 
liver transplantation. As noted by Finkler: “Economic 
cost will be used to refer to the price paid by the health 
care institution for the resources it consumes” (7). It is 
the economic cost that is important when one evaluates 
a new technology. It is essential to distinguish clearly 
this economic cost from the hospital’s accounting cost. 
Accounting cost refers to the “costs” attributed to pa- 
tients via the hospital’s accounting system. 
Hospital accounting systems accumulate cost infor- 
mation at the departmental level, and these accounting 
costs are then attributed to a patient on the basis of 
some statistic (e.g., length of stay). The attribution prob- 
lem is, in fact, compounded because before costs can be 
attributed to a patient, all of a hospital’s costs must be 
attributed first to hospital activities that directly serve 
patients and, therefore, generate income for the institu- 
tion. Thus, costs from nonincome-producing depart- 
ments such as administration, maintenance, dietary and 
the like must be attributed first to patient care centers 
and then, ultimately, to a patient. This process of cost 
attribution to the income-producing departments is ac- 
complished via an accounting technique called a multiple 
step-down, in which the first nonrevenue-producing cen- 
ter’s costs (e.g., administration) is “distributed to all the 
remaining centers (8). This process is continued until all 
of the nonrevenue-producing centers’ costs are distrib- 
uted to the revenue-producing centers. The resulting 
“costs” in the revenue producing center’s are then allo- 
cated to patients. This final allocation to the patient 
represents the hospital’s accounting costs. 
Two points are crucial concerning accounting costs: 
first, the “costs” that end up in the final revenue-pro- 
ducing cost centers are largely a function of the order of 
the accounting step-down. Thus, if one began the step- 
down first with maintenance costs rather than adminis- 
trative costs, the accounting costs in the laboratory (a 
revenue-producing cost center) would differ. Second, the 
final allocation from revenue-producing cost centers to 
patients is based upon average measures (e.g., length of 
stay, time in the operating room). From this brief de- 
scription of the accounting costs of a hospital, one can 
see that they differ from both charges and true economic 
costs. Indeed, they are neither. 
In looking at a program like liver transplantation, it is 
clear that the only appropriate measure is the economic 
costs of the program. In establishing a new program, it 
is important to assess the additional prices paid by the 
health care institution for the resources that the new 
program consumes (7). From the discussion above, 
charges can be dismissed out of hand, as they have 
nothing at all to do with the economic costs of a hospital. 
The accounting costs could be useful at an individual 
institution, but only if competing treatment modalities 
use similar final revenue-producing centers so that the 
bias due to the step-down procedure is minimized. It is 
clear that this condition is not met with liver transplan- 
tation. If one could make the case that similar revenue 
centers are used, one must then evaluate the effect of the 
final attribution of costs to patients within each final 
revenue center. If there is a bias in this allocation, then 
all of the final accounting costs will either over- or 
underestimate the economic costs. 
In reviewing studies that have attempted to evaluate 
the costs of liver transplantation, we see that there is a 
systematic bias that tends to underestimate the account- 
ing costs attributed to liver transplant patients. As dis- 
cussed above, costs are allocated from final revenue- 
producing centers to patients on the basis of some aver- 
age statistic. Thus, for example, patients are allocated a 
percentage of the total ICU costs as a function of their 
length of ICU stay, and surgical patients are allocated a 
percentage of the operating room costs on the basis of 
the time spent in the operating room, etc. Such allocation 
statistics, in effect, assign an average cost to each patient. 
This method works well if all patients in an ICU use 
similar amounts of resources and thus have similar eco- 
nomic costs. As patients in the same final revenue- 
producing center are more heterogeneous, the use of an 
allocation statistic based on averages will systematically 
understate the economic costs of very resource-intensive 
cases, and overstate the costs in low resource cases. 
Wagner et al. (9) have recently identified this type of 
cross-subsidization in an ICU and demonstrated that 
actual resource use differed by a factor of two in cases 
that were allocated the same accounting costs. 
Why is this detail important when considering liver 
transplantation? In a recent paper, Luebs (10) outlined 
some of the cost considerations in liver transplantation 
programs. By ignoring the charge information and focus- 
ing on the actual resources consumed, important infor- 
mation is provided. Luebs notes that, because of their 
liver transplant program, operating room staffing was 
increased, more high acuity nursing care was needed and 
the time necessary to clean a transplant isolation room 
was four times as long as for a normal isolation room. 
Therefore, when one looks at the allocation of accounting 
costs from any one of the final cost centers to liver 
transplant patients, the accounting costs systematically 
underestimate the economic costs of the program. 
Is it important to know what liver transplantation 
costs society? I think so, although others would question 
this assertion. Krom and Gips note that “liver transplan- 
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tation generates so many questions related to patho- 
physiology of the liver and transplantation, that results 
of related research and its effect on health care are 
spinoffs which cannot be estimated economically” (1 1). 
Furthermore, as Van Thiel et al. noted, benefits to the 
institution (and presumably the physician) include na- 
tional and international recognition. While each of the 
above is true, they clearly identify an inherent conflict 
of interest when those directly engaged in a line of 
research are asked to assess its worth. In juxtaposition 
to these assertions are those who would argue on eco- 
nomic grounds that liver transplantation is not justified. 
Of course, it costs less not to intervene with expensive 
medical treatments than to allow the disease to bring 
about death in its course. But a decision to withhold 
available, effective intervention, based solely on eco- 
nomic consideration, is repugnant to most physicians as 
well as to most of the public. What is the answer? 
An ongoing public debate about the use of sophisti- 
cated and costly medical technology such as liver trans- 
plantation is needed. Informed groups of citizens, with 
input from health care professionals, are probably best 
able to render such judgments free of the conflicts of 
interest inherent among the health professionals (5). 
Clearly needed is credible economic data about liver 
transplantation, which, as noted above, will be difficult 
to obtain given the complexity of hospital accounting. 
However, choosing to ignore this complexity may obfus- 
cate the understanding and impair the resolution of this 
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